NCT01198067终止1 期
Phase I Study of Pomalidomide in Relapsed or Refractory Waldenstrom Macroglobulinemia
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 15
- 试验地点
- 1
- 主要终点
- Number of Patients Experiencing MTD
研究概览
简要总结
This phase I trial studies the side effects and best dose of pomalidomide in treating patients with Waldenstrom macroglobulinemia that has returned after a period of improvement (relapsed) or does not respond to treatment (refractory). Pomalidomide may stimulate the immune system in different ways and stop cancer cells from growing.
详细描述
PRIMARY OBJECTIVES:
I. To determine the maximum tolerated dose (MTD) of pomalidomide in patients with relapsed or refractory Waldenstrom macroglobulinemia.
SECONDARY OBJECTIVES:
I. To evaluate the safety and toxicity profile of pomalidomide in patients with relapsed or refractory Waldenstrom macroglobulinemia.
II. To evaluate the efficacy of pomalidomide in patients with relapsed or refractory Waldenstrom macroglobulinemia.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Understand and voluntarily sign an informed consent form
- •Able to adhere to the study visit schedule and other protocol requirements
- •Waldenstrom's macroglobulinemia that has relapsed and/or is refractory to at least one prior line of therapy
- •All previous cancer therapy, including radiation, hormonal therapy and surgery, must have been discontinued at least 4 weeks prior to treatment in this study
- •Eastern Cooperative Oncology Group (ECOG) performance status of =< 2 at study entry
- •Serum creatinine =< 2.0 mg/dL
- •Creatinine clearance >= 45 ml/min
- •Total bilirubin =< 3 x upper limit of normal (ULN) or direct bilirubin =< 2 x ULN
- •Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2 x ULN
- •Platelet count >= 20 K/microL
- •Absolute neutrophil count >= 500 K/microL
- •Disease free of prior malignancies for >= 5 years with exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma in situ of the cervix or breast
- •Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL within 10 to 14 days prior to and again within 24 hours of starting pomalidomide and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before she starts taking pomalidomide; FCBP must also agree to ongoing pregnancy testing; men must agree to practice complete abstinence or agree use a latex condom during sexual contact with a FCBP while participating in the study, during dose interruptions and for at least 90 days following study drug discontinuation, even if they have had a successful vasectomy; all patients must be counseled at a minimum of every 28 days about pregnancy precautions and risks of fetal exposure
- •Able to take aspirin (325 mg) daily as prophylactic anticoagulation (patients intolerant to acetylsalicylic acid [ASA] may use therapeutic dose warfarin or low molecular weight heparin)
- •All study participants must be registered into the mandatory POMALYST REMS program, and be willing and able to comply with the requirements of the POMALYST REMS program
排除标准
- •Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form
- •Pregnant or breast feeding females; (lactating females must agree not to breast feed while taking pomalidomide or for 28 days after stopping pomalidomide)
- •Any medical or psychiatric condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study, or confounds the ability to interpret data from the study
- •Use of any other experimental drug or therapy within 28 days of the first dose of study drug
- •Known hypersensitivity to thalidomide or lenalidomide
- •The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs
- •Any prior use of pomalidomide
- •Concurrent use of other anti-cancer agents or treatments
- •Known positive for human immunodeficiency virus (HIV) or acute hepatitis A or acute or chronic active hepatitis B or C
- •Grade > 2 peripheral neuropathy
- •Neutrophil count < 1000 K/microL and/or
- •Platelet count < 100 K/microL unless infiltration by Waldenström's macroglobulinemia equals or exceed 60% of bone marrow cellularity
研究组 & 干预措施
Treatment (pomalidomide)
Experimental
Patients receive pomalidomide PO on days 1-28 or 1-21. Courses repeat every 21 or 28 days in the absence of disease progression or unacceptable toxicity.
干预措施: Pomalidomide (Drug)
结局指标
主要结局
Number of Patients Experiencing MTD
时间窗: Participants Experiencing Study Medication Maximum Tolerated Dose through Study Completion (Avg. 1 Year)
Maximum Tolerated Dose
次要结局
- Cycles Completed(Study Completion (Avg. 1 Year))
- Changes in Waldestrom Biomarkers(Through Study Completion (Avg. 1 Year))
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma or Newly Diagnosed or Relapsed or Refractory Intraocular LymphomaB-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt LymphomaCentral Nervous System LymphomaIntraocular LymphomaPrimary Diffuse Large B-Cell Lymphoma of the Central Nervous SystemRecurrent Adult Diffuse Large Cell LymphomaRetinal LymphomaNCT01722305Mayo Clinic29
已完成
2 期
Pomalidomide in Treating Patients With Kaposi Sarcoma and Human Immunodeficiency Virus InfectionHuman Immunodeficiency Virus 1 PositiveSkin Kaposi SarcomaNCT03601806AIDS Malignancy Consortium26
已完成
1 期
Pomalidomide in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System TumorsRecurrent Childhood Brain Stem GliomaRecurrent Childhood Visual Pathway GliomaRecurrent Primary Central Nervous System NeoplasmRefractory Primary Central Nervous System NeoplasmNeurofibromatosis Type 1NCT02415153National Cancer Institute (NCI)29
已完成
1 期
Pomalidomide After Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeChronic Myelomonocytic Leukemia-2High Risk Myelodysplastic SyndromeMyeloproliferative NeoplasmAcute Myeloid LeukemiaNCT02029950National Cancer Institute (NCI)50
已完成
3 期
Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-DependenceMPN-associated MyelofibrosisPrimary MyelofibrosisNCT01178281Celgene267